3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
48
Myelodysplastic Syndromes
23
Leukemia, Myelomonocytic, Chronic
10
Leukemia
7
Recurrence
6
Ovarian Neoplasms
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Primary Myelofibrosis
2
Neoplasms
2
Myeloproliferative Disorders
2
Melanoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Sarcoma, Synovial
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Pathologic Complete Response
1
Older Patients
1
Myeloid Malignancies
1
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Decitabine
×
1 year
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled